Search

Issue
Title
Authors
Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness
Borodavina E.V., Kutukova S.I., Shurinov A.Y., Vasil’eva E.B., Guz A.O., Grishkevich I.V., Karateeva S.D., Shakhmatova A.R., Slobodyanskiy R.S., Romanchuk O.V., Mukhitova M.R., Karpovich M.P., Dmitriev S.P., Saypeeva O.S., Tolpeykina K.A., Tolstov S.S., Makarova A.V., Tyugina Y.A., Ovchinnikova E.G.
New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
Mudunov A.M.
“Watch and wait” approach in the treatment of advanced radioiodine refractory differentiated thyroid cancer: a study of barriers and drivers of use
Borodavina E.V., Shurinov A.Y., Kutukova S.I., Nedozorova E.N., Malanchuk A.V., Semenchenko Y.V., Povarkov S.M., Narovenkova K.V., Khodkevich A.V., Komoza Y.V., Kofanova K.A., Dmitriev S.P., Vasilyeva E.B., Shikhamirova S.A., Gorshenina M.N., Volodina L.N., Snezhko O.A., Stativko O.A., Xenodokhov D.V., Dzhemageldieva Y.G., Khryapa A.I., Ulimaeva D.M., Dagba E.M., Volkonsky M.V., Filippova V.M., Skorina M.O., Romanchuk O.V., Andrienko I.I., Shorin M.V., Ishchenko A.A., Dumbrava R.A., Bolieva M.B., Tsarakhova F.V., Gojieva Z.A., Dzhamirzaeva S.S., Aidaeva P.Z., Maximov M.O., Usoltseva I.S., Milyukova A.O., Toporkova O.V., Sychev V.D., Rudakov S.A., Sagdieva S.T., Klochikhin M.A., Molokova V.V., Skotnikov R.A., Yeremina E.N., Panaseikin Y.A., Tyugina Y.A., Murzina Y.I., Podvyaznikov S.O.
Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
Cabanillas M.E., Takahashi S.
Diagnostic features of lung metastases differentiated thyroid cancer
Geliashvili T.M., Vazhenin A.V., Vasil’eva E.B., Afanas’eva N.G.
Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up
Shurinov A.Y., Borodavina E.V., Krylov V.V., Sigov M.A., Rodichev A.A., Ivanov S.A., Kaprin A.D.
18F-fluorodeoxyglucose positron emission tomography combined with computed tomography for the prediction of radioiodine therapy response in patients with metastatic differentiated thyroid cancer
Geliashvili T.M., Vazhenin A.V., Berezovskaya T.P., Afanasyeva N.G., Vasilyeva E.V., Garbuzov P.I., Krylov V.V.
Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
Gianoukakis A.G., Dutcus C.E., Batty N., Guo M., Baig M.
Follow-up after radioiodine remnant ablation in differentiated thyroid cancer: the view of nuclear medicine physician
Shurinov A.Y., Borodavina E.V.
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit
Wirth L.J., Durante C., Topliss D.J., Winquist E., Robenshtok E., Iwasaki H., Luster M., Elisei R., Leboulleux S., Tahara M.
Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Vasil’eva E.B., Vazhenin A.V., Geliashvili T.M., Fadeeva N.V., Garev A.V., Guz’ A.O.
Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States
Worden F., Rajkovic-Hooley O., Reynolds N., Milligan G., Zhang J.
Survival analysis of patients with advanced metastatic differentiated thyroid cancer
Borodavina E.V., Shurinov A.Y., Krylov V.V., Vasilev K.G.
Diagnostic score of malignancy risk in the people having a node in thyroid gland (Petrov Thyroid Cancer Score, PTCS)
Belyaev A.M., Berstein L.M., Vasil’ev D.A., Kostromina E.V., Krasil’nikova L.A., Krzhivitskiy P.I., Mikhet’ko A.A., Mishchenko A.V., Novikov S.N., Radzhabova Z.A., Sinyachkina D.A., Tsyrlina E.V.
Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues
Borodavina E.V., Shurinov A.Y., Krylov V.V.
A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer
Brose M.S., Panaseykin Y., Konda B., de la Fouchardiere C., Hughes B.G., Gianoukakis A.G., Park Y.J., Romanov I., Krzyzanowska M.K., Leboulleux S., Binder T.A., Dutcus C., Xie R., Taylor M.H.
The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment
Geliashvili T.M., Vazhenin A.V., Afanas’eva N.G.
Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
Borodavina E.V., Kutukova S.I., Shurinov A.Y., Krylov V.V.
Value of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in staging of patients with differentiated thyroid cancer after thyroidectomy during the first course of radioiodine therapy
Geliashvili T.M., Vazhenin A.V., Berezovskaya T.P., Vasilieva E.B., Afanasieva N.G., Krylov V.V., Garbuzov P.I.
Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer
Isaev P.A., Semin D.Y., Rumyantsev P.O., Il’in A.A., Pol’kin V.V., Agababyan T.A., Vasil’kov S.V., Medvedev V.S., Zhelonkina N.V.
1 - 20 of 20 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"